rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Aytu BioPharma, Inc.

AYTU · Nasdaq

Health CareBiotechnologyNot moving yet

AYTU stood above a rising 150-day average in 25 of the last 52 weekly readings, and has been out of that trend for the last 23 weeks. It is 11.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 23
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
35 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$120KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders35+5 on the quarter
New · exited4 · 1
Reported value$15.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCadded · filed 14 Aug 20264,990,238$9.6M+4,197,949+529.9%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 20261,086,812$2.3M00.0%
AWM Investment Company, Inc.unchanged · filed 14 Aug 2026619,574$1.3M00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026261,146$561K00.0%
DIADEMA PARTNERS LPreduced · filed 14 Aug 2026148,546$319K-204,531−57.9%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026105,326$226K-16,647−13.6%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026104,823$225K+11,100+11.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202693,647$201K+1,011+1.1%
CITADEL ADVISORS LLCadded · filed 14 Aug 202649,414$106K+12,573+34.1%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202647,048$101K00.0%
31 Mar 2023 – 30 Jun 2026
152534Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Abhinav Jain Company insiderDirector · last 28 Jul 20260 · 0
Carl Dockery Company insiderDirector · last 28 Jul 20262 · 1
Greg Pyszczymuka Company insiderChief Commercial Officer · last 28 Jul 20262 · 0
Jarrett Disbrow Company insiderChief Business Officer · last 28 Jul 20265 · 0
John Donofrio Jr. Company insiderDirector · last 28 Jul 20260 · 0
Joshua R. Disbrow Company insiderChief Executive Officer · last 28 Jul 202610 · 0
Ryan J. Selhorn Company insiderChief Financial Officer · last 28 Jul 20260 · 0
Vivian H. Liu Company insiderDirector · last 28 Jul 20260 · 0
Daniel Mack Company insider10% owner · last 6 Jun 20250 · 0
Wilmot B. Harkey Company insider10% owner · last 14 Jun 20240 · 0
Christopher Brooke Company insiderChief Operating Officer · last 11 Aug 20230 · 0
Mark K. Oki Company insiderChief Financial Officer · last 11 Aug 20231 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 30 Jun 202569.0%
Operating profit marginFY 2025 · to 30 Jun 2025-11.8%
Free cash flow marginFY 2025 · to 30 Jun 2025-3.3%
Return on capital employedFY 2025 · to 30 Jun 2025-12.8%
Debt to equityFY 2025 · to 30 Jun 20250.67×
Research spendFY 2025 · to 30 Jun 20252.0%
Share count trendFY 2025 · to 15 Sep 202510.4%
Cash and equivalentsFY 2025 · to 30 Jun 2025$31.0M
Free cash flowFY 2025 · to 30 Jun 2025−$2.2M

Analyst forecasts

No analyst forecasts yet.